FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226293575> ?p ?o ?g. }

• W4226293575 abstract "Elevated urinary 3-methoxytyramine (3MT) level at diagnosis was recently put forward as independent risk factor for poor prognosis in neuroblastoma. Here, we investigated the biologic basis underlying the putative association between elevated 3MT levels and poor prognosis.Urinary 3MT levels and prognosis were investigated in both retrospective Italian (N = 90) and prospective Dutch (N = 95) cohorts. From the Dutch Cancer Oncology Group cohort (N = 122), patients with available urinary 3MT and gene expression data (n = 90) were used to generate a 3MT gene signature. The 3MT gene signature score was then used to predict survival outcome in the Children's Oncology Group (N = 247) and German Pediatric Oncology Group (N = 498) cohorts and compared with other known gene signatures. Immunohistochemistry of MYCN and dopamine β-hydroxylase proteins was performed on primary tumors.Elevated urinary 3MT levels were associated with poor prognosis in a retrospective cohort and a prospective cohort. Moreover, elevated urinary 3MT levels were associated with eight differentially expressed genes, providing a 3MT gene signature that successfully predicted poor clinical outcome. Even among low-risk patients, high 3MT signature score was associated with poor 5-year overall survival (72% v 99% among low-risk patients with a low 3MT signature score), and the 3MT signature score was correlated with MYC activity in the tumor (R = 82%, P < .0001). Finally, a strong MYCN and weak dopamine β-hydroxylase staining of tumors derived from patients with elevated urinary 3MT levels was observed, linking MYC activity in the tumor to both catecholamine biosynthesis and elevated urinary 3MT levels.Elevated urinary 3MT is a promising biomarker for poor prognosis and reflects increased MYC activity in the tumor. Therefore, urinary 3MT levels should be measured at diagnosis and may assist in assessing risk." @default.
• W4226293575 created "2022-05-05" @default.
• W4226293575 creator A5006474472 @default.
• W4226293575 creator A5010154184 @default.
• W4226293575 creator A5017872011 @default.
• W4226293575 creator A5021790275 @default.
• W4226293575 creator A5030784484 @default.
• W4226293575 creator A5046131129 @default.
• W4226293575 creator A5056025258 @default.
• W4226293575 creator A5057873409 @default.
• W4226293575 creator A5060407769 @default.
• W4226293575 creator A5072840045 @default.
• W4226293575 creator A5074440176 @default.
• W4226293575 creator A5086277466 @default.
• W4226293575 creator A5091191169 @default.
• W4226293575 date "2022-05-01" @default.
• W4226293575 modified "2023-09-27" @default.
• W4226293575 title "Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma" @default.
• W4226293575 cites W1508539949 @default.
• W4226293575 cites W1586224227 @default.
• W4226293575 cites W1980134441 @default.
• W4226293575 cites W1987012261 @default.
• W4226293575 cites W2033037904 @default.
• W4226293575 cites W2061061698 @default.
• W4226293575 cites W2087593987 @default.
• W4226293575 cites W2096398040 @default.
• W4226293575 cites W2097120541 @default.
• W4226293575 cites W2101851382 @default.
• W4226293575 cites W2104096565 @default.
• W4226293575 cites W2121533951 @default.
• W4226293575 cites W2138809862 @default.
• W4226293575 cites W2149034978 @default.
• W4226293575 cites W2152420890 @default.
• W4226293575 cites W2156509269 @default.
• W4226293575 cites W2159971177 @default.
• W4226293575 cites W2258476076 @default.
• W4226293575 cites W2399722943 @default.
• W4226293575 cites W2493687124 @default.
• W4226293575 cites W2560479877 @default.
• W4226293575 cites W2569882255 @default.
• W4226293575 cites W2611071372 @default.
• W4226293575 cites W2781400086 @default.
• W4226293575 cites W2798190787 @default.
• W4226293575 cites W2902229746 @default.
• W4226293575 cites W2918013668 @default.
• W4226293575 cites W2945754738 @default.
• W4226293575 cites W2980828263 @default.
• W4226293575 cites W4211125082 @default.
• W4226293575 doi "https://doi.org/10.1200/po.20.00447" @default.
• W4226293575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35085004" @default.
• W4226293575 hasPublicationYear "2022" @default.
• W4226293575 type Work @default.
• W4226293575 citedByCount "3" @default.
• W4226293575 countsByYear W42262935752022 @default.
• W4226293575 countsByYear W42262935752023 @default.
• W4226293575 crossrefType "journal-article" @default.
• W4226293575 hasAuthorship W4226293575A5006474472 @default.
• W4226293575 hasAuthorship W4226293575A5010154184 @default.
• W4226293575 hasAuthorship W4226293575A5017872011 @default.
• W4226293575 hasAuthorship W4226293575A5021790275 @default.
• W4226293575 hasAuthorship W4226293575A5030784484 @default.
• W4226293575 hasAuthorship W4226293575A5046131129 @default.
• W4226293575 hasAuthorship W4226293575A5056025258 @default.
• W4226293575 hasAuthorship W4226293575A5057873409 @default.
• W4226293575 hasAuthorship W4226293575A5060407769 @default.
• W4226293575 hasAuthorship W4226293575A5072840045 @default.
• W4226293575 hasAuthorship W4226293575A5074440176 @default.
• W4226293575 hasAuthorship W4226293575A5086277466 @default.
• W4226293575 hasAuthorship W4226293575A5091191169 @default.
• W4226293575 hasBestOaLocation W42262935751 @default.
• W4226293575 hasConcept C104317684 @default.
• W4226293575 hasConcept C126322002 @default.
• W4226293575 hasConcept C143998085 @default.
• W4226293575 hasConcept C150194340 @default.
• W4226293575 hasConcept C188816634 @default.
• W4226293575 hasConcept C2776715637 @default.
• W4226293575 hasConcept C2779733811 @default.
• W4226293575 hasConcept C2781197716 @default.
• W4226293575 hasConcept C54355233 @default.
• W4226293575 hasConcept C71924100 @default.
• W4226293575 hasConcept C72563966 @default.
• W4226293575 hasConcept C77411442 @default.
• W4226293575 hasConcept C81885089 @default.
• W4226293575 hasConcept C86803240 @default.
• W4226293575 hasConceptScore W4226293575C104317684 @default.
• W4226293575 hasConceptScore W4226293575C126322002 @default.
• W4226293575 hasConceptScore W4226293575C143998085 @default.
• W4226293575 hasConceptScore W4226293575C150194340 @default.
• W4226293575 hasConceptScore W4226293575C188816634 @default.
• W4226293575 hasConceptScore W4226293575C2776715637 @default.
• W4226293575 hasConceptScore W4226293575C2779733811 @default.
• W4226293575 hasConceptScore W4226293575C2781197716 @default.
• W4226293575 hasConceptScore W4226293575C54355233 @default.
• W4226293575 hasConceptScore W4226293575C71924100 @default.
• W4226293575 hasConceptScore W4226293575C72563966 @default.
• W4226293575 hasConceptScore W4226293575C77411442 @default.
• W4226293575 hasConceptScore W4226293575C81885089 @default.
• W4226293575 hasConceptScore W4226293575C86803240 @default.
• W4226293575 hasIssue "6" @default.
• W4226293575 hasLocation W42262935751 @default.

• next